
Denali Therapeutics' AVLAYAH launch drives $7.8M revenue with strong patient and payer support
Denali Therapeutics reported a strong launch for its drug AVLAYAH, achieving $7.8 million in commercial revenue just in the second quarter after launch. The drug has gained significant interest from patients, physicians, and payers, with about 70% of...


